Figure 3.

Effects of CUDC‐907 on the expression of microenvironment chemokines. A, mRNA expression of CCL3, CCL4, CCL17, and CCL22, as measured by qRT‐PCR in CLL patient cells cultured with 10 μg/mL anti‐IgM and treated with CUDC‐907 for 24 h. B, Secretion levels of CCL3/4, as measured by quantitative ELISA, in supernatants of CLL patient cells cultured with anti‐IgM and treated with CUDC‐907. C, Expression of smCXCR4 in CLL patient cells not stimulated (left) or stimulated with 200 ng/mL CXCL12 (right), and treated with CUDC‐907 for 12 h. DMSO was used in controls. Cells were incubated with a CXCR4 primary antibody and a fluorescent labelled secondary antibody. The smCXCR4 signalling was measured with FACS. D, Representative Western blot showing levels of total and phosphorylated CXCR4 measured in lysates of CLL cells from two patient treated with CUDC‐907 for 12 h. E, Representative Western blot showing levels of ERK and phospho‐ERK in CLL patient treated as in (C)